Domantis Limited
Records under this name other than the patents Domantis Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,168,759 | Compositions Monovalent for CD28 Binding and Methods of Use Formerly held In force · High confidence | In force | High confidence | |
| US 9,085,629 | Compositions Monovalent for CD28 Binding and Methods of Use Formerly held In force · High confidence | In force | High confidence | |
| US 12,012,452 | Compositions Monovalent for CD28 Binding and Methods of Use Formerly held In force · High confidence | In force | High confidence | |
| US 8,895,010 | Antibody Polypeptides That Antagonize CD40L Formerly held In force · High confidence | In force | High confidence | |
| US 9,765,150 | Antibody Polypeptides That Antagonize CD40L Formerly held In force · High confidence | In force | High confidence | |
| US 10,196,451 | Methods of Treating Immune Diseases by Administering Antibody Polypeptides That Specifically Bind CD40L Formerly held In force · High confidence | In force | High confidence | |
| US 11,180,567 | Antibody Polypeptides That Antagonize CD40L Formerly held In force · High confidence | In force | High confidence | |
| US 10,072,089 | Polypeptides, Antibody Variable Domains and Antagonists Lapsed on the fee record Ended Sep 11, 2026 · High confidence | Lapsed on the fee record | Ended Sep 11, 2026 | High confidence |
| US 9,321,832 | Ligand Term ended Term ended May 16, 2026 · From the USPTO record | Term ended | Term ended May 16, 2026 | From the USPTO record |
| US 7,563,443 | Monovalent anti-CD40L antibody polypeptides and compositions thereof Term ended Term ended Mar 9, 2026 · From the USPTO record | Term ended | Term ended Mar 9, 2026 | From the USPTO record |